Cardiovascular Diseases

Lilly’s Lepodisiran Shows Durable Lipoprotein(a) Reduction in Phase 2 Trial

3 weeks ago talkbio0Tagged Cardiovascular Diseases, Interferes with, Lepodisiran, long-acting therapy, Lp(a ), RNA

lepodisiran, lipoprotein(a), Lp(a), cardiovascular disease, RNA interference, long-acting therapy

Merck Acquires Rights to Hengrui’s Oral Lp(a) Inhibitor in $2B Deal

4 weeks ago talkbio0Tagged Arteriosclerosis, Cardiovascular Diseases, Hengrui Pharmaceuticals, HRS-5346, licensing agreement, Lp(a ), Merck

Merck, Hengrui Pharmaceuticals, HRS-5346, Lp(a) inhibitor, cardiovascular disease, atherosclerosis, licensing agreement

Merck Secures $2B Deal with China’s Hengrui for Novel Heart Drug

4 weeks ago talkbio0Tagged Cardiovascular Diseases, Hengrui Pharmaceuticals, HRS-5346, Inhibitor, licensing agreement, Lipoprotein(a ), Merck

Merck, Hengrui Pharmaceuticals, HRS-5346, Lipoprotein(a) inhibitor, cardiovascular disease, licensing agreement

NFL Legend Jerome Bettis Joins CDC Foundation’s “Live to the Beat” Campaign to Tackle Heart Health in Black Community

3 months ago talkbio0Tagged beat, Bettis, Black Populations, Cardiovascular Diseases, Centers for Disease Control and Prevention (U.S.), Community, Foundations, heart health, Hypertensive disease, Jerome, NEFL gene

Jerome Bettis, CDC Foundation, Live to the Beat, cardiovascular disease, Black community, hypertension, heart health, NFL

FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease

3 months ago talkbio0Tagged Agonist, Approved, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes, GLP-1 receptor, Kidney Diseases, Ozempic, Risk, semaglutide, United States Food and Drug Administration

Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist

RyCarma Therapeutics Unveils New Leadership and Company Name, Expands Focus on Heart Failure Treatment

3 months ago talkbio0Tagged ARMGO, biotech company, Cardiovascular Diseases, Changing, Heart failure, Leadership, Pharma, Rycals, RyCarma, skeletal muscle diseases

RyCarma Therapeutics, ARMGO Pharma, ryanodine receptor, Rycals, heart failure, cardiovascular diseases, skeletal muscle diseases, biotech company, new leadership, company name change.